Sélection des publications de l'équipe 1

• Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, Paintaud G, Ternant D.
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
Br J Clin Pharmacol. 2016, 81 : 941-948

• Bonnier F, Brachet G, Duong R, Sojinrin T, Respaud R, Aubrey N,7, Baker MJ, Byrne HJ, Chourpa I.
Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy.
J Biophotonics. 2016 Aug 10. doi: 10.1002/jbio.201600015. [Epub ahead of print]

• Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.
Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.
Mol Pharm. 2016 Mar 1. [Epub ahead of print]

• Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Spano JP, Moussata D, Terebonne E, Paintaud G, Ternant D.
Bevacizumab serum concentrations influence overall survival in metastatic colorectal cancer patients.
Clin Pharmacokinet, 2016 Jun 16. [Epub ahead of print]

• Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A , Kryza T, Del Rio M, Guyetant S, Cadena Castaneda DC , Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V*and Heuzé-Vourc’h N*.
Down regulation of the neonatal fc receptor expression in non-small-cell lung cancer tissue is associated with a poor prognosis.
Oncotarget, 2016, accepté

• Dannepond C, Ternant D, Maruani A, Machet L, Paintaud G, Samimi M.
Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis.
Br J Dermatol. 2016, 174 : 198-200

• Darwiche W, Bejan-Angoulvant T, Angoulvant D, Babuty D, Fauchier L.
Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses.
Thromb Haemost. 2016 Sep 1;116(5). [Epub ahead of print]

• Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Clin Pharmacokinet. 2016 Jul 8. [Epub ahead of print]

• Lioger B, Ferreira-Maldent N, Cottier JP, Debiais S, Gyan E, Maillot F.
Rituximab for Sjögren syndrome-associated type II mixed cryoglobulinemic cerebral vasculitis.
Neurol Neuroimmunol Neuroinflamm. 2016 Jul 8;3(4):e253. eCollection 2016.

• Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D.
The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
MAbs. 2016 Aug 9:1-10. [Epub ahead of print]

• Patin F, Baranek T, Vourc’h P, Nadal-Desbarats L, Goossens JF, Marouillat S, Dessein AF, Descat A, Madji Hounoum B, Bruno C, Watier H, Si-Tahar M, Leman S, Lecron JC, Andres C, Corcia P, Blasco H.
Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: deleterious alteration of lipid metabolism.
Neurotherapeutics 2016 Jul 21. [Epub ahead of print]

• Pouplard C, Gruel Y.
A rapid test (STic Expert(®) ) for the diagnosis of heparin-induced thrombocytopenia - response to De Cooman and Devreese
Br J Haematol. 2016, 172 : 466-467

• Rollin J, Pouplard C, Gruel Y
Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.
Thromb Haemost. 2016 Jun 30;116(3). [Epub ahead of print]

• Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
J Immunol. 2016, 196 : 607-613